Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMNZOCK)

Drug Name	PF-05280586 DMNZOCK

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Follicular lymphoma	DISVEUR6	2A80	Phase 3	[1]
Cluster headache	DISKAXY9	8A81.0	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02213263) A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06). U.S. National Institutes of Health.